NeurogesX, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.
The Company's lead product, Qutenza?, is currently approved... More
Wednesday, Apr 112012, 11:04 AMShares of microcap drug developer NeurogesX (NGSX +30%) soar after saying the FDA has accepted its request for a meeting to discuss ongoing clinical studies of NGX-1998, its product candidate for neuropathic pain. Phase 2 studies were completed at the end of 2011. |Wednesday, Apr 112012, 11:04 AM| Comment!
Friday, Feb 102012, 10:20 AM
Tuesday, Feb 72012, 8:58 AMNeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its patch for HIV pain. The prescription-strength capsaicin patch didn’t meet its goals in studies for reducing pain caused by neuropathy linked to the virus, an FDA report says. |Tuesday, Feb 72012, 8:58 AM| Comment!